Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD
Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.
Obstructive sleep apnea has been a CPAP-and-mandibular-advancement-device category with positional therapy and surgery in selected patients. Tirzepatide carries OSA approval in patients with obesity, follow-on GLP-1 OSA programs are reading out, and upper airway pharmacological programs (atomoxetine plus oxybutynin combinations and others) are in late-stage trials. The category is acquiring real pharmacotherapy after decades of device-and-surgery defaults.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.